Copyright
        ©2014 Baishideng Publishing Group Inc.
    
    
        World J Gastroenterol. Aug 7, 2014; 20(29): 9691-9698
Published online Aug 7, 2014. doi: 10.3748/wjg.v20.i29.9691
Published online Aug 7, 2014. doi: 10.3748/wjg.v20.i29.9691
            Table 1 Vaccines recommended in immunocompromised inflammatory bowel disease patients
        
    | Infectious disease | Vaccine type | Recommendation | 
| Influenza | Inactivated trivalent virus | Recommended annually | 
| Pneumococcal disease | 23-valent purified capsular antigen | Recommended 5 yearly | 
| Hepatitis B virus | Recombinant peptide | Recommended standard or double dose schedule | 
| Human papilloma virus | Quadrivalent vaccine | In women according to local guidelines, standard schedule | 
| Tetanus-Diptheria | Toxoid | Recommended in vaccinated patients 10 yearly | 
| Measles-Mumps-Rubella | Live attenuated | Contraindicated | 
| Varicella zoster | Live attenuated | Contraindicated | 
| Yellow fever | Live attenuated | Contraindicated | 
| Cholera | Oral live | Contraindicated | 
| Oral killed | Use with caution | |
| Poliomyelitis | Oral live attenuated | Contraindicated | 
| Injectable inactivated | Recommended | |
| Meningococcal | Conjugated polysaccharide | Authorised yet not recommended | 
| C polysaccharide combined | Authorised yet not recommended | |
| Tuberculosis | BCG live vaccine | Always contraindicated | 
- Citation: Mill J, Lawrance IC. Preventing infective complications in inflammatory bowel disease. World J Gastroenterol 2014; 20(29): 9691-9698
- URL: https://www.wjgnet.com/1007-9327/full/v20/i29/9691.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i29.9691

 
         
                         
                 
                 
                 
                 
                 
                         
                         
                        